HALIFAX, Sept. 26, 2013 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid diagnostic technology and solutions, today announced the expansion of its organization with the hiring of key team members and new offices in the US and Switzerland as it makes its next move to strengthen its sales and business development programs. Joining MedMira are Kevin Jones, Ph.D. as Senior Director, Global Sales & Marketing and Markus Meile in the role of Senior Director, International Markets.
Dr. Jones brings over 20 years of significant industry experience to MedMira and has demonstrated successes in sales and marketing in medical, diagnostics, and life sciences sectors as well as product research, development and launch; building technology support apparatus; and business strategy. Most recently he worked with Avery Dennison Medical Solutions as Global Segment Market Manager. Prior to that he worked with EDP Biotech, Whatman Inc., and British BioCell InternationaI in various international roles. At MedMira, Dr. Jones will lead global sales and marketing programs, initially targeting the United States market with a focus on the launch of new products in the Reveal and Multiplo ranges as well as expanding Miriad, a research and development tool, into new market areas.
"MedMira, with its patented rapid flow-through technology that delivers almost instant results, is now ready to move boldly into new markets," said Dr. Jones shortly after his appointment. "The capital investment that was recently put in place, along with the new Reveal and Multiplo products that will be launched in the US and internationally beginning in 2014, will enable MedMira to grow significantly over the next two years."
To achieve its commercial targets MedMira has expanded its operations to include new offices in the United States, Switzerland, as well as a realigned sales and marketing team at the Company's corporate headquarters in Halifax, NS. Additionally, Markus Meile, a MedMira board member, has agreed to join the Company on a full-time basis. He will lead MedMira's international business development initiatives, cultivating and managing relationships with various government agencies, aid organizations, and NGOs to ensure the Company's rapid diagnostic solutions are a part of the efforts to address global healthcare challenges such as HIV and Hepatitis.
"I am very pleased that Markus can join us in a full-time role," said Dr. Jones. "He adds a wealth of experience in international markets and brings connections in the key organizations which will help us achieve our financial and corporate goals."
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The Company's rapid tests provide hospitals, labs, clinics and individuals with reliable, nearly instant diagnosis for diseases such as HIV and hepatitis C. MedMira tests are sold under the Reveal®, Multiplo™ and Miriad brands in global markets. MedMira's rapid flow-through HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada and the Company has sales and business development offices in the United States and Switzerland. For more information visit www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the Company's current expectation regarding future events including statements regarding possible approval and launch of new products, future growth, and new business opportunities. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: MEDMIRA INC.
For further information:
Andrea Young, Corporate Communications
T. 902 450 1588